JP7423598B2 - がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ - Google Patents

がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ Download PDF

Info

Publication number
JP7423598B2
JP7423598B2 JP2021504589A JP2021504589A JP7423598B2 JP 7423598 B2 JP7423598 B2 JP 7423598B2 JP 2021504589 A JP2021504589 A JP 2021504589A JP 2021504589 A JP2021504589 A JP 2021504589A JP 7423598 B2 JP7423598 B2 JP 7423598B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
certain embodiments
lif
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021504589A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019197903A5 (https=
JP2021521274A5 (https=
JP2021521274A (ja
Inventor
ジョアン・セオアネ・スアレス
ジュディット・アニド・フォルゲイラ
ヨハン・フランソン
ロビン・マシュー・ハレット
モニカ・パスクアル・ガルシア
エステル・ボンフィル・テシドル
エステル・プラナス・リゴル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
MedImmune Ltd
Original Assignee
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron, MedImmune Ltd filed Critical Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Publication of JP2021521274A publication Critical patent/JP2021521274A/ja
Publication of JPWO2019197903A5 publication Critical patent/JPWO2019197903A5/ja
Publication of JP2021521274A5 publication Critical patent/JP2021521274A5/ja
Priority to JP2024005463A priority Critical patent/JP2024054138A/ja
Application granted granted Critical
Publication of JP7423598B2 publication Critical patent/JP7423598B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021504589A 2018-04-12 2019-04-11 がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ Active JP7423598B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024005463A JP2024054138A (ja) 2018-04-12 2024-01-17 がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18382248.5 2018-04-12
EP18382248 2018-04-12
EP18382326 2018-05-14
EP18382326.9 2018-05-14
EP18382360 2018-05-25
EP18382360.8 2018-05-25
EP19382132.9 2019-02-22
EP19382132 2019-02-22
PCT/IB2019/000423 WO2019197903A1 (en) 2018-04-12 2019-04-11 Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024005463A Division JP2024054138A (ja) 2018-04-12 2024-01-17 がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ

Publications (4)

Publication Number Publication Date
JP2021521274A JP2021521274A (ja) 2021-08-26
JPWO2019197903A5 JPWO2019197903A5 (https=) 2022-04-18
JP2021521274A5 JP2021521274A5 (https=) 2022-04-18
JP7423598B2 true JP7423598B2 (ja) 2024-01-29

Family

ID=67060425

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504589A Active JP7423598B2 (ja) 2018-04-12 2019-04-11 がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ
JP2024005463A Ceased JP2024054138A (ja) 2018-04-12 2024-01-17 がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024005463A Ceased JP2024054138A (ja) 2018-04-12 2024-01-17 がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ

Country Status (11)

Country Link
US (1) US20210130453A1 (https=)
EP (1) EP3774895A1 (https=)
JP (2) JP7423598B2 (https=)
KR (1) KR20210021287A (https=)
CN (1) CN112585164A (https=)
AU (1) AU2019251289B2 (https=)
CA (1) CA3096779A1 (https=)
IL (1) IL277918A (https=)
MA (1) MA52231A (https=)
SG (1) SG11202009966SA (https=)
WO (1) WO2019197903A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3555132B1 (en) * 2016-12-19 2023-11-15 Medimmune Limited Antibodies against lif and uses thereof
AU2019269131B2 (en) * 2018-05-14 2024-02-22 Fundació Privada Institució Catalana De Recerca I Estudis Avançats Antibodies against LIF and dosage forms thereof
EP4069736A1 (en) * 2019-12-04 2022-10-12 MedImmune Limited Antibodies against lif and uses thereof
WO2021183370A1 (en) * 2020-03-11 2021-09-16 Purdue Research Foundation Compounds with immunomodulatory activity and therapeutic uses thereof
WO2023159152A2 (en) * 2022-02-17 2023-08-24 Immune-Onc Therapeutics, Inc. Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523796A (ja) 2010-04-05 2013-06-17 フンダシオ プリバーダ インスティトゥト ディンベスティガシオ オンコロジカ バル デブロン（ウベアチェイーオー） ヒト白血病阻害因子（ｌｉｆ）を認識する抗体および望ましくない細胞増殖に関連する疾患の治療における抗ｌｉｆ抗体の使用
JP2017527582A (ja) 2014-09-10 2017-09-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法
JP2019502664A (ja) 2015-11-27 2019-01-31 ファンダシオ プリヴァダ インスティタット ディンベスティガシオ オンコロジカ デ バル ヘブロン 望ましくない細胞増殖に関係する疾患の処置のための薬剤
JP2020512388A (ja) 2016-12-19 2020-04-23 モザイク バイオメディカルズ エス．エル．ユー． Ｌｉｆに対する抗体及びその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523796A (ja) 2010-04-05 2013-06-17 フンダシオ プリバーダ インスティトゥト ディンベスティガシオ オンコロジカ バル デブロン（ウベアチェイーオー） ヒト白血病阻害因子（ｌｉｆ）を認識する抗体および望ましくない細胞増殖に関連する疾患の治療における抗ｌｉｆ抗体の使用
JP2017527582A (ja) 2014-09-10 2017-09-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法
JP2019502664A (ja) 2015-11-27 2019-01-31 ファンダシオ プリヴァダ インスティタット ディンベスティガシオ オンコロジカ デ バル ヘブロン 望ましくない細胞増殖に関係する疾患の処置のための薬剤
JP2020512388A (ja) 2016-12-19 2020-04-23 モザイク バイオメディカルズ エス．エル．ユー． Ｌｉｆに対する抗体及びその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JEANNE MAGRAM; ET AL，LIF AS A NOVEL CANCER IMMUNOTHERAPY TARGET: MODULATING THE TUMOR MICROENVIRONMENT 以下備考，【ONLINE】，2017年，P1，https://web.archive.org/web/20180417065230/http://northernbiologics.com/wp-content/uploads/2017/10/AACR-Molecular-targets-2017-poster.pdf，WITH MSC-1, A HUMANIZED ANTI-LIF MONOCLONAL ANTIBODY
SHINDO YOSHITARO; ET AL，COMBINATION IMMUNOTHERAPY WITH 4-1BB ACTIVATION AND PD-1 BLOCKADE ENHANCES 以下備考，ANTICANCER RESEARCH，2015年，VOL:35, NR:1,，PAGE(S):129 - 136，https://ar.iiarjournals.org/content/35/1/129，ANTITUMOR EFFICACY IN A MOUSE MODEL OF SUBCUTANEOUS TUMOR

Also Published As

Publication number Publication date
AU2019251289A1 (en) 2020-11-26
CN112585164A (zh) 2021-03-30
AU2019251289A8 (en) 2021-01-14
EP3774895A1 (en) 2021-02-17
WO2019197903A1 (en) 2019-10-17
US20210130453A1 (en) 2021-05-06
CA3096779A1 (en) 2019-10-17
AU2019251289B2 (en) 2024-01-18
IL277918A (en) 2020-11-30
SG11202009966SA (en) 2020-11-27
WO2019197903A8 (en) 2020-02-20
MA52231A (fr) 2021-02-17
JP2024054138A (ja) 2024-04-16
KR20210021287A (ko) 2021-02-25
JP2021521274A (ja) 2021-08-26

Similar Documents

Publication Publication Date Title
JP7423598B2 (ja) がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ
JP7459173B2 (ja) Ｌｉｆに対する抗体及びその使用
JP2024160301A (ja) Ｌｉｆに対する抗体及びそれらの投与形態
JP7570929B2 (ja) Ｌｉｆを定量化する方法及びその使用
JP7520727B2 (ja) 癌を有する個人における抗ｌｉｆ抗体治療に対する反応を向上させるための方法
JP7603772B2 (ja) 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
EA047583B1 (ru) Комбинация ингибиторов lif и ингибиторов оси pd-1 для применения в лечении рака
HK40049059A (en) Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
EA044934B1 (ru) Антитела к lif и лекарственные формы на их основе
EA044914B1 (ru) Способы улучшения ответа на лечение с помощью антитела к lif у индивидуумов, страдающих от рака
EA049383B1 (ru) Способы улучшения ответа на лечение с помощью антитела к lif у индивидуумов, страдающих от рака
HK40042216A (en) Antibodies against lif and dosage forms thereof
BR122024020696A2 (pt) Anticorpo recombinante que se liga ao fator inibidor de leucemia e composição farmacêutica compreendendo o referido anticorpo
HK40040276B (zh) 抗lif抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220408

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230921

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240117

R150 Certificate of patent or registration of utility model

Ref document number: 7423598

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150